Diphenhydramine Hydrochloride

證據等級: L5 預測適應症: 0 個

目錄

  1. Diphenhydramine Hydrochloride
  2. Diphenhydramine Hydrochloride: Drug Repurposing Evaluation Report
    1. One-Sentence Summary
    2. Quick Overview
    3. Why is This Prediction Reasonable?
    4. Clinical Trial Evidence
    5. Literature Evidence
    6. Malaysia Market Information
    7. Safety Considerations
    8. Conclusion and Next Steps
      1. Data Gap Summary
    9. Disclaimer
## 藥師評估報告

Diphenhydramine Hydrochloride: Drug Repurposing Evaluation Report

One-Sentence Summary

Diphenhydramine hydrochloride is a first-generation antihistamine (H1 receptor antagonist) widely used for allergic conditions, motion sickness, and insomnia. The TxGNN model has not yet generated any predicted new indications for this drug. Currently, there are critical data gaps that must be resolved before a repurposing evaluation can proceed.

Quick Overview

Item Content
Original Indication Not available (license details pending)
Predicted New Indication None — no TxGNN predictions available
TxGNN Prediction Score N/A
Evidence Level L5 (No model prediction or supporting studies)
Malaysia Market Status ✓ Marketed (已上市)
Number of Registrations 34
Recommended Decision Hold

Why is This Prediction Reasonable?

Currently, the TxGNN model has not generated any predicted new indications for Diphenhydramine Hydrochloride, so a mechanistic plausibility assessment cannot be conducted at this time.

Detailed mechanism of action (MOA) data is not available in this evidence pack. Based on well-established pharmacology, Diphenhydramine is a first-generation H1 antihistamine that competitively blocks histamine at H1 receptors. It also has anticholinergic, antitussive, antiemetic, and mild sedative properties. These multi-receptor activities could theoretically support repurposing hypotheses, but no specific TxGNN predictions have been generated to evaluate.

Before any repurposing analysis can proceed, the following must be completed:

  1. Resolution of the DrugBank ID mapping (currently null) to enable TxGNN knowledge graph linkage.
  2. Successful execution of the TxGNN prediction pipeline to generate candidate indications.
  3. Retrieval of MOA data from DrugBank to support mechanistic reasoning.

Clinical Trial Evidence

Currently no related clinical trials registered — no predicted indication available to search against.

Literature Evidence

Currently no related literature available — no predicted indication available to search against.

Malaysia Market Information

Authorization Number Product Name Dosage Form Approved Indication
(Details pending) (Details pending) (Details pending) (Details pending)

Note: 34 product registrations were identified through NPRA query, but detailed license information (authorization numbers, product names, dosage forms, and approved indications) has not yet been populated in this evidence pack. Data retrieval from NPRA is required.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data are not yet available in this evidence pack and must be retrieved from the NPRA database or package insert PDFs.

Conclusion and Next Steps

Decision: Hold

Rationale: This evidence pack contains critical data gaps that prevent any meaningful repurposing evaluation. No TxGNN predicted indications have been generated, the DrugBank ID is unmapped, MOA data is missing, license details are empty, and safety information is unavailable. The evaluation cannot proceed until these foundational data elements are resolved.

To proceed, the following is needed:

  1. [Blocking] Resolve DrugBank ID mapping — Query DrugBank for “Diphenhydramine Hydrochloride” (expected: DB01075) and update the evidence pack
  2. [Blocking] Run TxGNN prediction pipeline — Execute KG + DL prediction with the mapped DrugBank ID to generate candidate new indications
  3. [Blocking] Retrieve NPRA license details — Populate authorization numbers, product names, dosage forms, and approved indication text for the 34 identified registrations
  4. [High] Retrieve MOA data — Query DrugBank API for mechanism of action, pharmacodynamics, and target information
  5. [High] Retrieve safety data — Download and parse package insert PDFs from NPRA for key warnings, contraindications, and drug interactions
  6. [Medium] Collect evidence — Once predicted indications are available, query ClinicalTrials.gov, PubMed, and ICTRP for supporting evidence

Data Gap Summary

ID Category Item Severity Remediation
DG001 Drug Level NPRA Package Insert (Warnings/Contraindications) Blocking Download and parse PDF from NPRA website
DG002 Drug Level Mechanism of Action (MOA) High Query DrugBank API
— Drug Level DrugBank ID Blocking Query DrugBank (likely DB01075)
— Prediction TxGNN Predicted Indications Blocking Run prediction pipeline after DrugBank mapping
— Regulatory NPRA License Details High Re-query NPRA with full field extraction

Disclaimer: This report is for research purposes only and does not constitute medical advice. Any drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Hak Cipta © 2026 Projek MyTxGNN. Untuk tujuan penyelidikan sahaja. Bukan nasihat perubatan.

This site uses Just the Docs, a documentation theme for Jekyll.